covid19

 Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351(CORRESPONDENCE) Shen X, Tang H, Pajon R, et al.　〔N Engl J Med. 2021 Jun 17;384(24):2352-2354〕SARS-CoV-2変異株B.1.429およびB.1.351に対する中和活性（Editorへのレター）　（日本語概要） Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant Shinde V, Bhikha S, Hoosain Z, et al.　〔N Engl J Med. 2021 May 20;384(20):1899-1909〕B.1.351変異株に対するNVX-CoV2373 COVID-19ワクチンの有効性　（日本語概要） Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine Heath P, Galiza EP, Baxter DN, et al.　〔N Engl J...

 Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine  Sadoff J, Le Gars M, Shukarev G, et al.　〔N Engl J Med. 2021 May 13;384(19):1824-1835〕 Ad26.COV2.Sワクチンの第I/IIa相臨床試験の中間解析結果　（日本語概要）  Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19  Stephenson KE, Le Gars M, Sadoff J, et...

 Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial Ramasamy MN, Minassian AM, Ewer KJ, et al.　〔Lancet. 2021 Dec 19;396(10267):1979-1993〕若年成人および高齢者を対象としたChAdOx1 nCoV-19ワクチン2回接種の安全性と免疫原性（COV002） ― 単盲検無作為化比較第II/III相試験　（日本語概要） Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in...

 Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination (Correspondence)  Widge AT, Rouphael NG, Jackson LA, et al.　〔N Engl J Med. 2021 Jan 7;384(1):80-82〕 SARS-CoV-2ワクチンmRNA-1273接種後の反応の持続性（Editorへのレター）　（日本語概要） Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine  Baden LR, El Sahly HM, Essink B, et al.　〔N Engl J...

 Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults.  Mulligan MJ, Lyke KE, Kitchin N, et al.　〔Nature. 2020 Oct;586(7830):589-593〕 成人でのCOVID-19 RNAワクチンBNT162b1の第I/II相試験　（日本語概要） Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates  Walsh EE, Frenck RW Jr, Falsey AR, et al.　〔N Engl J...